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Abstract
Gd-LC6-SH is a thiol-bearing DOTA complex of gadolinium designed to bind plasma albumin at the conserved
Cys34 site. The binding of Gd-LC6-SH shows sensitivity to the presence of competing thiols. We hypothesized that
Gd-LC6-SH could provide magnetic resonance imaging (MRI) enhancement that is sensitive to tumor redox state
and that the prolonged retention of albumin-bound Gd-LC6-SH in vivo can be exploited to identify a saturating dose
above which the shortening of MRI longitudinal relaxation time (T 1) of tissue is insensitive to the injected gadolinium
dose. In the Mia-PaCa-2 pancreatic tumor xenograft model in SCID mice, both the small-molecule Gd-DTPA-BMA
and the macromolecule Galbumin MRI contrast agents produced dose-dependent decreases in tumor T 1. By
contrast, the decreases in tumor T 1 provided by Gd-LC6-SH at 0.05 and 0.1 mmol/kg were not significantly different
at longer times after injection. SCID mice bearing Mia-PaCa-2 or NCI-N87 tumor xenografts were treated with
either the glutathione synthesis inhibitor buthionine sulfoximine or the thiol-oxidizing anticancer drug Imexon, re-
spectively. In both models, there was a significantly greater increase in tumor R1 (=1/T 1) 60 minutes after injection
of Gd-LC6-SH in drug-treated animals relative to saline-treated controls. In addition, Mercury Orange staining for
nonprotein sulfhydryls was significantly decreased by drug treatment relative to controls in both tumor models.
In summary, these studies show that thiol-bearing complexes of gadolinium such as Gd-LC6-SH can serve as
redox-sensitive MRI contrast agents for detecting differences in tumor redox status and can be used to evaluate
the effects of redox-active drugs.
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Introduction
In mammalian cells, response to oxidative stress is brought about by
the NRF2 transcription factor that triggers the transactivation of
genes that contain at least one antioxidant response element in their
promoters. These include genes encoding for the glutamate-cysteine
ligase catalytic and modifier subunits, which catalyze the rate-limiting
step in glutathione synthesis, as well as genes that encode for proteins
such as glutathione reductase, thioredoxin, thioredoxin reductase,
peroxiredoxin, and sulfiredoxin, which are required for restoring
oxidized intracellular thiols to their reduced states [1]. Reduced
glutathione (GSH) accounts for more than 90% of nonprotein thiols in
cells; is a tripeptide of glutamate, cysteine, and glycine; and is synthesized
intracellularly by the consecutive actions of γ-glutamylcysteine syn-
thetase (γ-GCS) and glutathione synthetase. Feedback inhibition of
γ-GCS by the final product GSH results in this step becoming rate lim-
iting for de novo intracellular synthesis of GSH [2]. GSH is involved in
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the detoxification of xenobiotics, including chemotherapeutics, by con-
jugation of electrophilic groups on the molecule with the nucleophilic
sulfhydryl of GSH. These can be nonenzymatic reactions or conjuga-
tions catalyzed by glutathione-S-transferase and GSH peroxidase. Con-
jugation negatively impacts the antitumor activities of platinum drugs,
nitrogen mustards, doxorubicin, and nitrosoureas [3]. Detoxification of
electrophilic drugs can also occur in the extracellular space through the
action of plasma membrane-bound γ-glutamyl transpeptidase (γ-GT),
another enzyme regulated by NRF2, on extracellular GSH [4]. Drugs
such as Imexon and 2-deoxy-glucose have been reported to produce
oxidative stress in cultured cells by decreasing intracellular concentrations
of reduced glutathione and cysteine [5–7]. These disruptions in thiol
metabolism have been reported to radiosensitize cultured tumor cells
and xenograft tumor models [7,8], effects that could be augmented by
concomitant use of the γ-GCS inhibitor L-buthionine-SR-sulfoximine
(BSO) [5] or mitigated by concomitant use of the thiol antioxidant
N -acetylcysteine [5,7]. Although N -acetylcysteine remains extracellular,
it is thought to affect scavenging of intracellular reactive oxygen species
produced by ionizing radiation by increasing intracellular GSH [9].
Elevated GSH concentrations have also been reported to comprise
one of the mechanisms of tumor cell resistance to cyclophosphamide,
and this resistance could be abolished in cultures by treating the tumor
cells with BSO [10].
There is, therefore, much interest in the development of methods to
selectively modify tumor redox status to therapeutic advantage [3,11].
Tissue redox status is also important in other pathologies, including
aging, diabetes mellitus, and cardiovascular, inflammatory, immune,
and neurodegenerative diseases. A perturbed redox balance is also a
hallmark of several fibrotic diseases, and GSH and N -acetylcysteine
have been used clinically for the treatment of idiopathic pulmonary
fibrosis and cystic fibrosis [12,13]. Although the extracellular GSH pool
is small, the redox potential of the GSSG/GSH pool has been measured
to be more reducing than other thiol-disulfide couples in plasma, and it
has been suggested that GSH provides the reducing equivalents to
maintain the redox states of other thiol pools [14]. GSH is made in cells
and is readily transported out to the extracellular space; current evi-
dence indicates a role for the multidrug resistance–associated proteins
(MRP/ABCC) in the export of GSH as well as oxidized glutathione
(GSSG), glutathione S -conjugates, and GSH adducts formed in re-
sponse to oxidative or electrophilic challenge [13]. NRF2 control of
the expression of MRP and γ-GT [1] provides cells with the ability
to control both intracellular and extracellular redox states in response
to oxidative stress.
Biomedical imaging methods for interrogating spatial variations in
redox status within tumors would be desirable for their relatively
noninvasive nature, especially when the target tissue is not readily
amenable to biopsy. Opstad et al. [15] have quantified GSH in menin-
giomas with localized 1H magnetic resonance spectroscopy (MRS) in a
clinical setting, although the insensitivity of MRS limits the spatial res-
olution of the technique. Thelwall et al. [16] have used 1H-decoupled
13C MRS imaging to follow the incorporation of exogenously infused
13C-labeled glycine into glutathione in tumor-bearing rats. The dis-
advantages of their technique include the need for very long infusions
with 13C-labeled substrate, as well as long imaging times to achieve rel-
atively coarse image resolutions. Nonetheless, these methods offer a
window into in vivo glutathione metabolism. Nitroxide radicals, be-
cause of their ability to participate in redox reactions, have been used
as spin probes in electron paramagnetic resonance spectroscopy and
imaging to monitor in vivo redox status [17]. The conversion of
paramagnetic nitroxyl radicals to diamagnetic hydroxylamine molecules
in reducing microenvironments in tissue can also be observed as a
decrease of signal in T 1-weighed magnetic resonance imaging (MRI)
[18]. Whether imaged by electron paramagnetic resonance or MRI,
nitroxide concentrations can be used to monitor tissue redox status
in vivo because the rate of disappearance of the nitroxide signal is
dominated by chemical reduction rather than clearance from the animal
[19]. The nitroxide doses used in these measurements are typically in
the range of 0.75 to 1.5 mmol/kg, and nitroxide-enhanced MRI has
recently been used to produce spatial maps of bioreductive activity in
multiple tissues and organs in mice [20]. Gadolinium-based MRI con-
trast agents possess longitudinal water-proton relaxivities (r1) that are an
order of magnitude or more greater than the r1 of nitroxide radicals,
allowing the use of proportionately smaller doses in MRI studies. Tu
et al. [21] have described a combination of a spiropyran group and a
Gd-DO3A complex that exhibits an r1 that is sensitive to NADH. We
have reported the development of thiol-bearing DOTA complexes of
gadolinium designed to bind plasma albumin at the conserved Cys34
site. The in vitro binding affinities of these complexes with human
serum albumin were studied using homocysteine, an endogenous thiol
known to bind to the Cys34 site in plasma albumins [22]. One of these
complexes, Gd-LC6-SH (Figure 1), demonstrated prolonged retention
in mice after intravenous administration, and this in vivo retention
could be released by chasing with homocysteine [23]. In the present
work, we have used the albumin binding of this complex to identify
a “saturating” dose, above which changes in tumor longitudinal relax-
ation time (T 1) at longer times after injection were insensitive to the
injected dose. The r1 of Gd-LC6-SH is higher when the complex is
bound to albumin compared with the unbound molecule. We have
therefore hypothesized that the change in tumor T 1 (ΔT 1) produced
by Gd-LC6-SH injected at the saturating dose will be dependent on the
local concentration of thiols capable of competing for binding albumin
at Cys34; a smaller ΔT 1 would be expected in highly reducing regions
compared with that in oxidizing regions. We have compared the ΔT 1
of Mia-PaCa-2 xenografts in mice treated with saline or BSO, and
NCI-N87 tumor xenografts in mice treated with saline or Imexon,
and have correlated differences in MRI results with treatment-related
changes in tumor thiol content. In both models, there was a significantly
greater increase in tumor R1 (=1/T 1) 60 minutes after injection of Gd-
LC6-SH in drug-treated animals relative to saline-treated controls. In
addition, Mercury Orange staining for nonprotein sulfhydryls (NPSHs)
was significantly decreased by drug treatment relative to controls in both
tumor models. Multidose Imexon treatment also produced a tumor
growth delay in NCI-N87 tumors relative to saline-treated controls.
Figure 1. The Gd-LC6-SH compound.
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Materials and Methods
Mice, Tumors, and Drugs
All animal experiments were conducted in accordance with the
guidelines of the Institutional Animal Care and Use Committee of
the University of Arizona. Mia-PaCa-2 pancreatic carcinoma cells
and NCI-N87 gastric carcinoma cells were obtained from the ATCC
(Manassas, VA). Tumor cells were established as xenografts on the
flanks of 4-week-old female SCID mice by the Experimental Mouse
Shared Service of the Arizona Cancer Center. For MRI contrast agent
characterization studies, mice were imaged when tumors were 150 to
1100 mm3 as estimated by orthogonal caliper measurements. In the
first drug study, mice were randomized to control (saline) or BSO
groups when Mia-PaCa-2 tumors were 172 ± 83 mm3. BSO (Sigma-
Aldrich, St Louis, MO) was prepared as a 250-mM solution at pH 7.4
in phosphate-buffered saline (PBS). Mice were administered either
BSO (5 mmol/kg, i.p.) or saline (0.5 mL per 25 g, i.p.) on day 1, fol-
lowed by a second dose 4 hours before MRI on day 2, and a third dose
4 hours before sacrifice and harvest of tumors on day 3. In the second
drug study, mice were randomized to control (saline) or Imexon groups
when NCI-N87 tumors were 111 ± 44 mm3. Imexon (Amplimexon;
AmpliMed Corp, Tucson, AZ) was prepared as a 15-mg/ml solution,
and mice were administered either Imexon (150 mg/kg, i.p.) or saline
(0.25 ml per 25 g, i.p.) 2 hours before MRI on day 1, followed by a
second dose 2 hours before sacrifice and harvest of tumors on day 2. In
the third drug study, 48 mice bearing NCI-N87 tumors were admin-
istered either Imexon (150 mg/kg, i.p.) or saline (0.25 ml per 25 g, i.p.)
on days 5, 9, and 13 after inoculation. Twelve mice (six with saline +
six with Imexon) were used in a substudy to follow tumor volumes
for 39 days. Twenty-four mice (12 with saline + 12 with Imexon) were
used in a substudy to assess tumor thiols by histologic staining with
Mercury Orange; these tumors were harvested 2 hours after dosing
on day 13 (vide infra). The remaining 12 mice (6 with saline + 6 with
Imexon) were imaged by MRI, with the dose on day 13 being admin-
istered 2 hours before imaging.
MRI Contrast Agents
Gd-LC6-SH was synthesized as detailed previously [22,23]. Gd-
LC6-SH and Gd-DTPA-BMA (OmniScan; GE Healthcare, Princeton,
NJ) were prepared as 25- and 50-mM solutions in PBS at pH 7.4.
Galbumin (BioPAL, Inc, Worcester, MA) is a macromolecule compris-
ing several Gd-DTPA molecules covalently attached to bovine serum
albumin (BSA) and was purchased as a solution, which was 1.76 mM
in terms of BSA and 31.2 mM in terms of Gd. Before in vivo use, this
solution was diluted with PBS to produce solutions that were 7.8 and
15.6 mM in Gd at pH 7.4.
Magnetic Resonance Imaging
All MRI measurements were made on a Bruker Biospec MR im-
ager with a 7-T horizontal bore magnet equipped with 600 mT/m
self-shielded gradients (Bruker Biospin, Billerica, MA). Mice were
anesthetized using isoflurane (1.5% in O2, 1 L/min) and cannulated
at the tail vein for injections. A pressure transducer pad for monitor-
ing respiration (SA Instruments, Inc, Stony Brook, NY) was placed
under the anesthetized animal, and the mouse was gently secured in a
plastic holder. The animal was loaded into a 25-mm-ID small animal
imaging Litz coil (Doty Scientific, Columbia, SC), and the entire
assembly was centered inside the MRI magnet. Animal body temper-
ature was maintained using a forced warm air system and monitored
using a rectal temperature probe (SA Instruments). After acquisition
of scout MRI images, eight gradient-echo (GRE) images were ac-
quired using the following parameters at a scan time of 80 seconds
per image: repetition time (TR) = 78 milliseconds, echo time (TE) =
3.5 milliseconds, matrix = 256 × 256, field of view = 3 × 3 cm, slice
thickness = 2 mm, number of averages (NA) = 4, and eight varying
flip angles ranging from 5° to 75°. These images were used for calcu-
lating a precontrast T 1 map and proton density map. This was fol-
lowed by a coregistered dynamic GRE series (TR = 78 milliseconds,
TE = 3.5 milliseconds, flip angle = 75°, NA = 1, number of repetitions =
60, scan time = 20 minutes) during which the contrast medium was
administered. After the start of the dynamic series, contrast agent solu-
tion was administered as a tail vein injection at the appropriate dose for
1 minute and chased with 0.15 ml of saline injected over 1 minute. After
the dynamic series, 10 coregistered GRE images (TR = 78 milliseconds,
TE = 3.5 milliseconds, flip angle = 75°, NA = 12) were acquired at
regular intervals to 60 minutes after injection of the contrast agent.
Together with the precontrast proton density map, these 10 postcontrast
T 1-weighted images were used to compute postcontrast T 1 maps at the
10 time points after injection of gadolinium.
Tissue Sections
Mercury Orange (1-[4-chloromercuriophenylazo]-2-naphthol) is a
histochemical stain for thiols. Over the years, several groups have op-
timized solvent, exposure time, and temperature conditions to improve
selectivity for NPSHs over protein sulfhydryl groups and other macro-
molecules and lipids [24–27]. Hedley et al. [28] report good agreement
between NPSH values determined by a high-performance liquid chro-
matography method and NPSH quantified by fluorescence image anal-
ysis of cryostat sections of clinical tumor biopsies stained with Mercury
Orange. Tumor sections were cut, fixed, stained, and mounted on
slides by the Tissue Acquisition and Cellular/Molecular Analysis shared
service of the Arizona Cancer Center as per the method of Hedley et al.
[28]. Briefly, tumors were rapidly harvested from mice after sacrifice by
cervical dislocation under anesthesia (4% isoflurane in O2). This was
done the day after imaging to allow for complete clearance of Gd-
LC6-SH from the animals. Harvested tumors were immediately
placed into cryovials containing Tissue-Tek OCT embedding medium
(Sakura FinetekUSA, Torrance, CA) and frozen in isopentane immersed
in liquid nitrogen. Serial sections of tumor tissue (3 μm) were cut using a
Microm HM550 Cryostat (Thermo Fisher Scientific, Waltham, MA),
and two tissue sections were picked up on charged slides (SuperFrost
Plus charged microscope slides, no. 48311-703, VWR, Arlington
Heights, IL). One section was stained with freshly prepared Mercury
Orange (Sigma-Aldrich) on ice. Mercury Orange was dissolved in
acetone, and ultrapure water was added to produce a 75-μM solution
in 9:1 (vol/vol) acetone-water. Cut sections were rapidly placed in the
Mercury Orange solution and stained on ice for 5 minutes. This was
followed by two rinses with 9:1 acetone-water on ice and a final rinse
with PBS, after which the slides were coverslipped with a glycerol-based
nonfluorescent medium (no. 475904, Mowiol 4-88, EMD Millipore,
San Diego, CA). The second tissue section was fixed in acetone, rinsed,
and stained with hematoxylin and eosin (H&E).
Mercury Orange Control Experiment
In a separate experiment, serial sections of a Mia-PaCa-2 tumor
were cut and picked up on slides as described above, after which the
slides were immersed for 20 minutes at room temperature in either
PBS, PBS containing 4 mM 5,5′-dithiobis-(2-nitrobenzoic acid)
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(DTNB), or PBS containing 5 mM dithiothreitol (DTT). After this
incubation, four sections from each condition were stained with
Mercury Orange as described above, whereas additional two sections
incubated in PBS for 20 minutes were stained with H&E.
Light Microscopy
H&E-stained slides were imaged at 200× on a DMetrix Model
DX-40 slide scanner using the DMetrix digitalRetina software
(DMetrix, Inc, Tucson, AZ). Digitized images were typically very
large data files and could be viewed offline at magnifications ranging
from 0.6× to 40× using the DMetrix digitalEyepiece software. They
were saved as 24-bit color and 8-bit grayscale TIFF files.
Fluorescence Microscopy
Fluorescence images of Mercury Orange–stained slides were cap-
tured with a Leica SP5 confocal microscope using a 10× objective
lens with HeNe laser excitation centered at 543 nm and fluorescence
emission collected in the 585 ± 20-nm band. A motorized scanning
stage was used to acquire contiguous tiles over a field large enough to
cover the entire tumor section. An optical zoom factor of 3 was used
to reduce intensity mismatches at tile edges. The amplifier gain, mag-
nification, field of view, and digitization matrix size per tile were kept
constant across all slides in a given study to permit quantitative com-
parison of fluorescence intensities between individual tumors. Fused
images were saved as 24-bit color and 8-bit grayscale TIFF files.
Data Analysis (Microscopy)
Eight-bit grayscale TIFF files of the tiled fluorescence images were
analyzed using a program written in IDL (ITT Visual Information
Solutions, Boulder, CO). Images were interactively thresholded to set
background-level pixels to zero intensity. One or more regions of inter-
est (ROIs) were then hand-drawn to cover the entire tumor while using
the parallel H&E images for visual reference. Mean image intensity (on
the 8-bit scale of 0-255) was then computed from all nonzero pixels
within the tumor ROIs, and the results were expressed as mean ±
standard deviation for each group.
Data Analysis (MRI)
MRI images were analyzed using a program written in IDL to cal-
culate the longitudinal relaxation time (T 1) and rate (R1 = 1/T 1), as
well as the time-varying changes in T 1 and R1 (ΔT 1 and ΔR1), on a
per-pixel basis and also from ROIs drawn around the tumor and the
muscle. Precontrast T 1 maps and corresponding proton density maps
were calculated by pixelwise fitting of the eight precontrast images ac-
quired using eight flip angles to the GRE signal equation. Postcontrast
T 1 maps were calculated from the precontrast proton density maps and
the corresponding postcontrast T 1-weighted image using the GRE sig-
nal equation. ROIs were drawn around the tumor and muscle using a
coregistered T2-weighted scout image as visual guide. Mean ΔT 1 and
ΔR1 values were computed from the tumor and muscle ROIs, and the
results were expressed as mean ± standard deviation for each group.
Statistical Analysis
A two-tailed unpaired Student’s t test (Microsoft Excel, Microsoft
Corp, Redmond,WA) was used to compare ROImeans of ΔT 1 orΔR1
between groups imaged using various gadolinium agents at different
doses and to compare treatment groups in the drug studies.
Results
MRI Contrast Agent Dose-Response
At 7 T and 37°C in PBS, the r1 of Gd-DTPA-BMA was measured
to be 3.03/mM/sec, whereas the r1 of Galbumin was measured to be
86.16/mM/sec on a per-BSA basis and 4.86/mM/sec on a per-Gd basis.
Under these same conditions, the r1 of Gd-LC6-SH is 3.23/mM/sec,
increasing to 4.74/mM/sec when bound to human serum albumin
[22]. The time-varying change of tumor and muscle T 1 were measured
in vivo after injection of the two small-molecule contrast agents at
0.05 mmol/kg and the standard dose of 0.1 mmol/kg. The macromol-
ecule agent Galbumin was injected at 0.016 and 0.032 mmol Gd/kg
because significantly higher doses produced unacceptable numbers of
animal death soon after injection. Figure 2 depicts an axial T2-weighted
MRI image of a SCID mouse bearing a Mia-PaCa-2 tumor xenograft,
as well as coregistered T 1 maps calculated before and 60 minutes after
administration of 0.05 mmol/kg Gd-LC6-SH. The change in T 1 (ΔT 1)
relative to precontrast calculated on a pixel-by-pixel basis and averaged
in tumor and muscle ROIs is plotted as a function of time in Figure 3.
Dynamic data in the first 20 minutes after injection were acquired
without signal averaging and were therefore relatively noisy, and have
been omitted for visual clarity. As seen in Figure 3A, at 20 minutes
(1200 seconds) after injection, Gd-LC6-SH decreased Mia-PaCa-2
tumor T 1 by 0.48 seconds at the half-dose and 0.54 seconds at the
Figure 2. T2-weighted axial MR image of a SCID mouse showing a Mia-PaCa-2 tumor xenograft on the right flank (left, arrow), and the
corresponding pre-Gd T 1 map (center) and T 1 map obtained 60 minutes after injection of 0.05 mmol/kg Gd-LC6-SH (right). The T 1 map
legend runs from 0.0 (black) to 2.0 (white) seconds.
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standard dose, decreasing in both cases to 0.38 seconds by 60 minutes
after injection. The corresponding changes in muscle T 1 were smaller,
from 0.18 seconds at 20 minutes after injection to 0.15 seconds at
60 minutes after injection at both doses. As shown in Figure 3B, at
the half-dose, Gd-DTPA-BMA decreased Mia-PaCa-2 tumor T 1 by
0.28 seconds and muscle T 1 by 0.10 seconds at 20 minutes after
injection, decreasing to 0.16 seconds in tumor and 0.07 seconds inmuscle
by 60 minutes after injection. At the standard dose, Gd-DTPA-BMA
decreased tumor T 1 by 0.50 seconds and muscle T 1 by 0.20 seconds
at 20 minutes after injection, decreasing to 0.30 seconds in tumor
and 0.13 seconds in muscle by 60 minutes after injection. The ΔT 1-
versus-time plots for both Gd-LC6-SH and Gd-DTPA-BMA show
evidence of varying degrees of washout. Whereas Gd-DTPA-BMA
demonstrates classic dose-dependent washout kinetics (Figure 3B), the
plots for Gd-LC6-SH indicate some degree of retention of the agent in
both tumor and muscle such that there is a lack of dose dependence in
tumor andmuscle at longer times after injection (Figure 3A). The macro-
molecule Galbumin is not expected to be renally filtered, and the
kinetics of this agent were essentially time-invariant between 20 and
60 minutes after injection. Galbumin reduced Mia-PaCa-2 tumor T 1 by
∼0.18 seconds and muscle T 1 was reduced by ∼0.12 seconds at a gado-
linium dose of 0.016 mmol/kg, whereas at a dose of 0.032 mmol/kg,
tumor T 1 was reduced by ∼0.39 seconds and muscle T 1 was reduced
by ∼0.14 seconds (Figure 3C).
At 60 minutes after injection, the decrease in tumor T 1 produced
by Galbumin and Gd-DTPA-BMA was dose dependent at the two
doses tested (Figure 4; P < .05 for both agents). At 60 minutes after
injection, the tumor ΔT 1 produced by Galbumin at 0.032 mmol/kg was
roughly twice the tumor ΔT 1 produced by Galbumin at 0.016 mmol/kg
(Figure 4). This is consistent with negligible clearance of the macro-
molecule from the animal during the course of the experiment. The
tumor ΔT 1 produced by Gd-DTPA-BMA at 0.1 mmol/kg was also
approximately twice that at 0.05 mmol/kg (Figure 4), consistent with
renal clearance of this small molecule from the animal with first-order
kinetics. The decrease in tumor T 1 at 60 minutes after injection pro-
duced by Gd-LC6-SH at 0.05 mmol/kg was comparable to that pro-
duced using twice the dose (Figure 4). This is consistent with binding
of a fraction of the injected Gd-LC6-SH to serum albumin (or other
nonfiltered targets) in the animal, with continuous renal clearance of
the unbound fraction such that by 60 minutes after injection, there
is no significant difference in tumor ΔT 1 produced by Gd-LC6-SH at
the two doses. The decrease in tumor T 1 at 60 minutes after injection
produced by Gd-LC6-SH at the two doses was also comparable to that
produced by 0.032 mmol Gd/kg Galbumin but greater than that pro-
duced by 0.016 mmol Gd/kg Galbumin (Figure 4). Given the similar
per-Gd relaxivities of albumin-bound Gd-LC6-SH and Galbumin, this
indicates that the dose of Gd-LC6-SH required to saturate its nonfilter-
able binding sites in vivo after bolus intravenous administration is less than
0.05 mmol/kg but greater than 0.016 mmol/kg. Muscle ΔT 1 at 60 min-
utes after injection was not dose dependent for any agent, with only a
modest shortening of T 1 relative to measurement variability (Figure 4).
Microscopy of H&E-Stained Sections
Mia-PaCa-2 pancreatic carcinoma cells in H&E-stained sections
appeared diffusely packed and without significant signs of desmoplasia.
Figure 3. Decreases in the longitudinal relaxation time T 1 of muscle (circles and squares) and Mia-PaCa-2 tumor xenograft (triangles) at
various times after injection of (A) Gd-LC6-SH, (B) Gd-DTPA-BMA, and (C) Galbumin. The gadolinium doses in A and B were 0.05 mmol/kg
(gray) or 0.1 mmol/kg (black), and those in C were 0.016 mmol/kg (gray) or 0.032 mmol/kg (black). The number of animals at each condition
(n) varied from 8 to 22. Results are expressed as mean ± standard deviation at each time point.
Figure 4. Summary of the changes (before contrast minus after
contrast) in T 1 of Mia-PaCa-2 tumor and muscle at 60 minutes
after injection of Gd-LC6-SH, Gd-DTPA-BMA, and Galbumin at
two different doses of gadolinium. The number of animals at each
condition (n) varied from 8 to 22. Results are expressed asmedian±
standard deviation (*,**P < .05).
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NCI-N87 gastric carcinoma cells in H&E-stained sections appeared to
be organized into glandular structures (Figure 5A). In both tumor
types, the H&E-stained sections were used as a visual guide when draw-
ing ROIs on fluorescence images of corresponding Mercury Orange–
stained sections.
Mercury Orange Control Experiments
Figure 5B depicts Mercury Orange–stained fluorescence microscopy
images of Mia-PaCa-2 tumor sections treated with 4 mM DTNB in
PBS, 5 mM DTT in PBS, and PBS (control), for 20 minutes at room
temperature before staining and fixation. Mercury Orange binds to
thiols, and oxidation of thiols in the tissue sections by the disulfide
DTNB produced a significant decrease inMercury Orange staining rel-
ative to the tumor that was treated with only PBS (Figure 6A). Treat-
ment of tumor sections with the reducing agent DTT resulted in a
small increase in Mercury Orange staining relative to the PBS control
that did not rise to statistical significance (Figure 6A). Two tumor sec-
tions were incubated in PBS for 20 minutes at room temperature and
then stained with H&E. These sections did not show obvious signs of
tissue degradation but did show increased nuclear staining and intersti-
tial swelling compared with sections that were fixed and stained without
preincubation in PBS.
Mercury Orange Fluorescence Measurements of NPSH
Multidose regimens of BSO injections have previously been noted
to provide sustained decreases in tumor GSH, with the nadir occur-
ring 4 hours after an injection [29]. Both MRI and harvest of Mia-
PaCa-2 tumors were performed 4 hours after a BSO injection.
Tumors were harvested for staining with Mercury Orange on the day
after MRI to reduce the likelihood of cross-reactivity with residual
Gd-LC6-SH in the tumor. Treatment with BSO decreased Mercury
Orange staining intensity by 42% in Mia-PaCa-2 tumors relative to
saline-treated controls (P < .001), whereas treatment with Imexon de-
creased Mercury Orange staining intensity by 14% in NCI-N87 tumors
relative to saline-treated control tumors (P < .05; Figure 6B). This re-
sponse in Mia-PaCa-2 tumors is somewhat less than the 50% to 55%
decreases in Mercury Orange fluorescence that have been observed by
Vukovic et al. [30] in cervical cancer xenograft tumors after BSO
treatment but is comparable to the decrease in GSH measured by
Kuppusamy et al. [17] in RIF-1 tumors after BSO treatment.
MRI of Tumor Response to BSO and Imexon
The change in longitudinal relaxation rate, ΔR1, in a given pixel can
be related to Gd-LC6-SH concentration in that pixel using Equation 1
ΔR1 =
1
T1
−
1
T10
= r1ð Þef f : Gd½ ð1Þ
where T 1 is the longitudinal relaxation time at a given time after injec-
tion of gadolinium, T 10 is the precontrast longitudinal relaxation time,
[Gd] is the total concentration of Gd-LC6-SH in the pixel at that given
time, and (r1)eff is the weighted average relaxivity of the Gd-LC6-SH
between its various forms (free or bound to small molecules versus
bound to albumin or other large molecules). Figure 7 depicts the in-
crease in tumor relaxation rate 60 minutes after tail vein injection of
0.05 mmol/kg Gd-LC6-SH (ΔR1_60 min) in mice treated with saline
or drug. A significant increase in ΔR1_60 min was measured in Mia-Pa-
Ca-2 tumors from BSO-treated mice relative to saline-treated mice
Figure 5. (A) H&E-stained light microscopy (left) and Mercury Orange–stained fluorescence microscopy (right) images of adjacent 3-μm
sections cut from an NCI-N87 tumor xenograft. (B) Example Mercury Orange–stained fluorescence microscopy images of Mia-PaCa-2
tumor sections treated with 4 mM DTNB in PBS (left), 5 mM DTT in PBS (center), and PBS (right) for 20 minutes at room temperature
before staining and fixation. Scale bar, 100 μm in all panels.
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(Figure 7; P < .034). A significant increase in ΔR1_60 min was measured
in NCI-N87 tumors from Imexon-treated mice relative to saline-treated
mice (Figure 7; P < .001).
NCI-N87 Tumor Response to Multidose Imexon
We have also investigated the effect of a multidose regimen of Im-
exon on NCI-N87 tumor xenografts (Figure 8). SCID mice bearing
NCI-N87 xenografts were administered saline or Imexon on days 5,
9, and 13 after tumor inoculation. Mean tumor volumes in the
Imexon-treated group were smaller than in the saline group, with
the difference becoming statistically significant in the period 31 to
39 days after inoculation (Figure 8A); the experiment was terminated
at that point because of excessive tumor burdens in some mice in the
saline group. In the drug studies reported in Figure 6, tumors were
harvested from the same animals that were imaged by MRI, on the
day after MRI, after the mice had received an additional dose of saline
or drug before tumor harvest. Figure 8 (B and C ) reports Mercury
Orange and MRI measurements on separate cohorts of mice, with
the tumor harvest or MRI occurring 2 hours after saline or Imexon
administration on day 13 after inoculation. For the study reported in
Figure 8B, four tumors were excluded from each group to yield eight
size-matched tumors each in the saline (100 ± 21 mm3) and Imexon
(106 ± 33 mm3) treatment groups. Mercury Orange fluorescence was
significantly higher in the saline group relative to the Imexon group
2 hours after treatment on day 13 after inoculation (Figure 8B; n = 8,
P < .05), indicative of a lower level of reduced thiols in the Imexon
group. In the corresponding MRI study, the increase in longitudinal
relaxation rates at 60 minutes after injection of 0.05 mmol/kg Gd-
LC6-SH (i.e., ΔR1_60 min) in NCI-N87 tumors was significantly
higher in Imexon-treated animals compared with saline-treated animals
(Figure 8C ; n = 6, P < .03).
Discussion
Previous results with Gd-LC6-SH [22,23] suggest that it binds to the
Cys34 residue in human serum albumin, a residue that is conserved
in mammalian albumins. The longitudinal relaxivity (r1) of Gd-LC6-
SH is 47% higher when it is bound to albumin, compared with the
r1 of the molecule by itself or when it is bound to another small
molecule. In more reducing microenvironments, competition for
binding to the Cys34 by endogenous small-molecule thiols is likely
to decrease the bound fraction of Gd-LC6-SH. Thus, we hypothe-
sized that a higher relaxation rate would be expected in an oxidizing
tumor microenvironment relative to a reducing tumor microenviron-
ment. A confounding factor is that the change in tumor relaxation
rate could also be a function of the injected dose of Gd. We have
exploited the prolonged retention of albumin-bound Gd-LC6-SH
in the mouse to identify a dose and time after injection at which
the change in tumor R1 is insensitive to injected dose. Albumin-
bound Gd-LC6-SH is protected from renal filtration, and we hypoth-
esized that, at sufficiently long times after injection (e.g., 60 min),
bulk Gd-LC6-SH not bound to a macromolecular target has been
Figure 6. (A) Mean ± standard deviation Mercury Orange fluorescence in Mia-PaCa-2 tumor sections (n = 4) treated with DTNB and DTT
relative to PBS (control). (B) Mean ± standard deviation Mercury Orange fluorescence in Mia-PaCa-2 tumors after BSO treatment (n = 8;
*P < .001) and NCI-N87 tumors after Imexon treatment (n = 8; **P < .05) relative to saline treatment (control).
Figure 7. Mean ± standard deviation of the change in longitudinal
relaxation rates (ΔR1) at 60 minutes after injection of 0.05 mmol/kg
Gd-LC6-SH in Mia-PaCa-2 tumors after saline or BSO treatment
(n = 8; *P < .034) and NCI-N87 tumors after single-dose treatment
with saline or Imexon (n = 8; **P < .001).
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cleared and a pseudo steady-state is established between bound and
free Gd-LC6-SH in tumor. The results in Figures 3 and 4 are consis-
tent with the saturation of Cys34 binding sites for Gd-LC6-SH on
serum albumin when a dose of 0.05 mmol/kg is used, such that by
60 minutes after injection, there is still significant shortening of tumor
T 1 but not significantly less so than when a dose of 0.1 mmol/kg
is used. We have explored the utility of ΔR1_60 min as a biomarker
of tumor redox status in Mia-PaCa-2 tumor xenografts after treat-
ment with the glutathione synthesis inhibitor BSO and in NCI-
N87 tumors after treatment with the thiol-oxidizing drug Imexon.
An advantage of being able to wait 60 minutes after injection is that
it allows more time for tissues to recover from any potential pertur-
bation of redox caused by injection of the tracer itself. Systemic per-
turbations are further minimized by using half the standard dose of
gadolinium in these experiments.
From Equation 1, in the dose-insensitive regime, tumor ΔR1_60 min
can be related to (r1)eff, which in turn depends on the ratio of free versus
bound Gd-LC6-SH in the tumor. We see a significant increase in
ΔR1_60 min (Figure 7) and decrease in Mercury Orange staining
(Figure 6B) of Mia-PaCa-2 tumors with BSO treatment relative to
control tumors. This is consistent with an oxidizing effect of BSO treat-
ment on Mia-PaCa-2 tumors, leading to increased binding of Gd-LC6-
SH to albumin in the tumor with a consequent increase in ΔR1_60 min
after treatment. Studies of the chemical reactivity of Imexon with the
sulfur atom of small-molecule thiols showed that binding could occur
by two routes: a classic opening of the aziridine ring of Imexon to form
a drug-GSH conjugate or opening of the iminopyrrolidone ring of
Imexon to yield a thiazoline conjugate with cysteine [31]. In human
8226 multiple myeloma cells, Imexon induced a concentration-
dependent decrease in both oxidized and reduced glutathione levels
that was correlated with the induction of apoptosis [5]. Furthermore,
in an initial phase 1 clinical trial of Imexon in cancer patients, Imexon
decreased the plasma levels of cystine in proportion to the area under
the curve of drug achieved in the blood of the study participants. This
finding is consistent with a depletion of reduced sulfhydryls in cells
after Imexon therapy, leading to depletion of plasma cystine, which
comprises the primary cysteine storage form used to replenish intra-
cellular GSH [32]. The plasma half-life of Imexon in mice is 12 to
15 minutes after intraperitoneal injection, whereas the nadir in tissue
GSH levels occurs 2 to 4 hours after administration [33]. The ΔR1_60 min
of NCI-N87 tumors was significantly larger in Imexon-treated mice
than in saline-treated mice (Figures 7 and 8C). This is consistent with
an oxidizing effect of Imexon treatment on NCI-N87 tumors, leading
to increased binding of Gd-LC6-SH to albumin in the tumor and, con-
sequently, an increase in ΔR1_60 min after treatment. These MRI results
are supported by assays of tissue thiol levels using the histologic stain
Mercury Orange (Figures 6B and 8B). An important difference be-
tween the MRI and Mercury Orange measurements is that, whereas
theMRI contrast agent Gd-LC6-SH would be expected to respond pri-
marily to extracellular thiols (the agent is not expected to cross the cell
membrane), the Mercury Orange would be expected to stain for both
intracellular and extracellular thiols with the former being the dominant
pool [14]. However, it is reasonable for there to be metabolic con-
nectivity between the intracellular and extracellular pools of thiols in
a tumor, especially given the known control of γ-GT and MRP expres-
sion by the NRF2 transcription factor [1]. Although gadolinium com-
plexes generally do not cross the cell membrane by themselves, it should
be noted that SPARC secretion by stromal fibroblasts is a feature of
many tumors [34]. It has been suggested that high levels of SPARC
can lead to accumulation of albumin in tumors [35]; this could con-
ceivably lead to increased tumor retention of albumin-bound Gd-LC6-
SH.We have not investigated either tumor model for potential changes
in albumin uptake after drug treatment.
GSH and cysteine can chemically reduce and repair DNA radicals
produced by ionizing radiation, potentially serving as a mechanism of
radioresistance in tumors. Research efforts to identify agents that will
augment the therapeutic index of radiation therapy have shifted toward
more targeted biologic agents that either modulate redox reactions
within tumor cells or are activated under certain redox conditions
[36]. Moreno-Merlo et al. [37] have demonstrated that NPSH levels
Figure 8. Multidose treatment of mice bearing NCI-N87 tumor xenografts with saline or Imexon. (A) Mean ± standard deviation tumor
volumes versus days after inoculation (n = 6; P < .05 in period indicated, arrows indicate treatment). (B) Mean ± standard deviation
Mercury Orange fluorescence after Imexon treatment relative to saline control on day 13 after inoculation (n = 8; *P < .05). (C) Mean ±
standard deviation of the change in longitudinal relaxation rates (ΔR1) at 60 minutes after injection of 0.05 mmol/kg Gd-LC6-SH in NCI-N87
tumors after treatment with saline or Imexon on day 13 after inoculation (n = 6; *P < .03).
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are ∼50% greater in hypoxic regions of human cervical cancer xeno-
grafts, relative to better oxygenated tumor tissue, and that hypoxic
regions that are proximal to blood vessels have greater levels of NPSH
than normoxic regions or distal hypoxic regions [38]. But in a limited
study, tumor NPSH levels were not predictive of the outcome in pa-
tients with locally advanced cervical carcinomas who were treated with
radiation therapy [39]. Difficulties in relating tumor NPSH levels to
outcome in patients can be appreciated from the finding that GSH
and N -acetylcysteine inhibit the activation and function of MMP-9,
a matrix metalloproteinase implicated in the malignant progression of
precancerous lesions, by preserving the cysteine sulfur blockage of the
active site in the propeptide [40]. The physiological small-molecule
thiols cysteine, homocysteine, and GSH have been reported to cause
inactivation of transforming growth factor β, which functions as a tumor
suppressor in early stages of carcinogenesis but can induce epithelial-to-
mesenchymal transition of cells in late-stage tumors and promote tumor
growth and metastasis [41]. Thus, high levels of tumor NPSH may
influence both cancer progression and tumor response to therapies
but toward opposing clinical outcomes. This highlights the need for
noninvasive techniques for measuring tumor redox in vivo. We have
presented a paradigm wherein thiol-containing complexes of gado-
linium such as Gd-LC6-SH can serve as redox-sensitive MRI contrast
agents. One can envision a role for redox-sensitive MRI in personalized
cancer therapy, from prospectively identifying a patient subset that
might be more (or less) susceptible to redox-dependent drug therapy,
to monitoring tumor response to novel redox-active therapies by imag-
ing. Further optimization of these gadolinium agents must focus on
increasing the difference in r1 between free and albumin-bound gado-
linium, as well as fine-tuning the sensitivity of the complexes to the
presence of competing small-molecule thiols.
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